Desmoid tumors (DTs) are unusual neoplasms of mesenchymal origin that exhibit locally invasive behavior. Surgical resection is the initial treatment of choice for DTs. For patients with recurrent or unresectable disease, however, medical options are limited. Sorafenib is a multikinase inhibitor with known antitumor activity in various cancers via suppression of the PI3K/Akt/mTOR pathway. Here, we examined the effects of sorafenib on patient-derived DT cell lines, with the aim of characterizing the efficacy and molecular mechanism of action. Early passage DT-derived cells were treated with increasing doses of sorafenib (0-10 µM) and demonstrated up to 90% decrease in proliferation and invasion relative to controls. Signaling arrays identified multiple potential targets of sorafenib in the Ras/MEK/ERK and PI3K/Akt/mTOR signaling cascades. Immunoblot analysis revealed that sorafenib inhibited Akt, MEK and ERK phosphorylation, and this effect correlated with inhibition of total Akt and total MEK, while total ERK levels remained unchanged. Sorafenib also inhibited 4E-BP1 phosphorylation, and this effect correlated with decrease of p-eIF4E and total eIF4E. Finally, in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus, sorafenib decreased phosphorylation of the ribosomal protein and mTOR effector S6K in an additive manner. Taken together, our results suggest that sorafenib suppresses DT proliferation and invasion via inhibition of Ras/MEK/ERK and PI3K/Akt/mTOR signaling pathways with additional effects on translation. Sorafenib may be a promising therapeutic option in the treatment of DTs. Additional studies in DT patients are warranted to examine the efficacy of combination therapy using sorafenib.
Introduction
Desmoid tumors (DTs), or aggressive fibromatosis, are mesenchymal tumors with a dense, infiltrative character that can produce disfigurement, functional deficits and death (1, 2) . Although rare in the general population, DTs are a common cause of morbidity in patients with familial adenomatous polyposis (FAP) (3) . Surgical resection is the initial treatment of choice for DTs, but medical options are limited for recurrent or unresectable disease. While several studies have reported partial response using drug treatments and radiation therapy, effective systemic therapies for DTs remain elusive, in large part, due to the limited understanding of the molecular mechanisms that drive DT aggressiveness and progression (4) (5) (6) .
Tyrosine kinase inhibitors such as imatinib mesylate (Gleevec) and sunitinib (Sutent) have met with partial success in treating patients with DTs (7) (8) (9) (10) . A recent Phase II study prospectively examined the effect of imatinib in 51 patients and demonstrated long-term partial response in only three (6%) patients (11) . Forty-eight patients (94%) had stable disease at 2 months of treatment and 43 patients (84%) had stable disease at 4 months of treatment. Consistent with these findings, we previously showed variable levels of tyrosine kinase activity in DTs, in keeping with the heterogeneous nature of this disease and mixed response to tyrosine kinase inhibitors (12) . These reports underscore the need for more effective systemic treatments for unresectable or metastatic DTs.
Sorafenib is a multikinase inhibitor that targets tyrosine kinases including vascular endothelial growth factor receptor, c-Kit and platelet-derived growth factor receptor (PDGFR) (13) (14) (15) . Preclinical in vitro cell line assays suggest that sorafenib activity varies with the particular signaling pathways driving growth of different tumor types. In patients with DTs, sorafenib treatment demonstrated partial antitumor activity including significant improvement of symptoms in 16/22 patients; however, the precise molecular mechanisms underlying sorafenib activity in DTs are unknown (16) . Here, we examined the antitumor effects of sorafenib on short-term patient-derived DT cell lines, in order to further characterize the efficacy and mechanism of action.
Materials and methods

Human DT samples
Human DTs were obtained from surgical specimens resected from patients under a protocol approved by the institutional review board at Brigham and Women's Hospital (BWH). Patient characteristics are described in Table 1 . The tumor specimen was minced in supplemented growth medium and plated on tissue culture dishes. After 24 h at 37°C, the minced tumor was forced through 100 µm nylon mesh cell strainer under sterile conditions, while being washed with growth medium. The wash was then centrifuged at 1500 r.p.m. for 5 min, with the resultant pellet resuspended in growth medium and plated in 6-well plates. The following day, cells that were non-adherent to flasks were discarded. The remaining cells were maintained and expanded as primary DT-derived cell lines.
Cell lines
DT cell lines were obtained directly from patient tumors resected in the operating room, as described above. Only short-term primary tumor cell lines were used for experiments and authenticated by cell morphology. Cells were cultured in MesenPro RS™ Medium supplemented with the associated MesenPro RS™ Growth Supplement, 2 mM l-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Human dermal fibroblasts (HDFs) were obtained from American Type Culture Collection (ATCC) (Manassas, VA) and authenticated by the supplier by short tandem repeat profiling. Cells were cultured in DMEM containing 10% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin and passaged for fewer than 6 months after receipt. Unless otherwise indicated, cell culture reagents were purchased from Life Technologies (Grand View, NY). Cells were maintained at 37°C in a humidified incubator at containing 5% CO 2 .
Proliferation assay
Cells were plated in 96-well plates at a concentration of 2000 cells per well in normal growth medium, and incubated overnight at 37°C in a humidified incubator containing 5% CO 2 . On the following day, control or treated medium was added to wells. For treated cells, sorafenib tosylate (LC Laboratories, Woburn, MA) was dissolved in dimethyl sulfoxide to make a stock solution, and serial dilutions of this stock were prepared in growth medium, ranging from final concentrations between 1 and 25 μM, with a concentration of dimethyl sulfoxide not exceeding 1% of the final concentration. Each concentration was assayed in triplicate. Cells were incubated for 72 h after addition of drug. Proliferation was determined using the CellTiter 96® AQ ueous Non-Radioactive Cell Proliferation Assay kit from Promega Corporation (Madison, WI) according to the manufacturer's instructions. Briefly, after treatment, assay mix was added to each well (20 µl per well), and the plate was incubated at 37°C for an additional 4 h. The absorbance of each individual well was then determined at 490 nm. Proliferation index was determined by dividing the absorbance values of the treated wells by the absorbance values of the untreated wells.
Invasion assay
To assess invasion, DT-derived cells were first dyed with a fluorescent red vital dye, CellTracker™ Red CMTPX (Life Technologies), 24 h prior to seeding in invasion chambers. The dye was initially diluted in dimethyl sulfoxide to a stock solution of 5 mM, which was then used at a final concentration of 5 μM in solution. Cells were initially plated in 10 cm plates. These cells were then incubated for 45 min with the vital dye, and then re-covered with growth medium. The following day, these cells were plated at a concentration of 20 000 cells per well in 24-well plates containing Matrigel BioCoat Invasion Chambers (BD Biosciences, Bedford, MA), with growth medium containing either 5 µM sorafenib or vehicle. Each concentration (sorafenib or vehicle) was assayed in duplicate. Twenty-four hours after seeding with drug solution, the medium in the invasion chambers was aspirated, and the chambers were twice washed in phosphate-buffered saline (PBS). The upper portion of the chamber was cleaned with a cotton swab, and rewashed in PBS. The remaining invasive cells on the lower portion of the chamber were fixed with 100% methanol. To fix the invasion membranes, the methanol was washed from the chambers in PBS, and the invasion chamber membranes were carefully removed from the insert using a surgical #11 microblade, and the membranes were fixed on glass slides using VECTASHIELD® Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). Invasive cells were then imaged using a fluorescent microscope, with images captured using an attached whole slide scanner. Cells were counted as cells per HPF (number of cells per 1 mm 2 ) to evaluate ~80% of each membrane, and each experiment was performed in duplicate. 
Abbreviations
Signaling array
Protein lysates collected for immunoblot analysis were also utilized for commercially available antibody signaling arrays (PathScan® receptor tyrosine kinase signaling antibody array chemiluminescent readout kit and PathScan® Akt antibody array chemiluminescent readout kit, Cell Signaling Technology, Danvers, MA). Immediately before performing the assay, protein lysates were diluted to a concentration of 1 mg/ml. The assay was then conducted according to the manufacturer's protocol.
Results were captured using a Fuji digital imaging system.
Immunoblot analysis
Protein lysate concentrations were determined using a Bio-Rad Bradford protein assay (Hercules, CA). 
Statistical analysis
Means and standard deviations were calculated for each experiment. Student's t-test was performed to evaluate differences between each experimental condition (P < 0.05 was considered statistically significant).
Results
Sorafenib decreases proliferation and invasion in DT-derived cells
To investigate the effect of sorafenib in DT cells, we isolated and expanded cell lines from DTs obtained immediately following surgical resection from patients. We then performed MTS assay on three different cell lines derived from both familial and sporadic tumors following treatment with increasing doses of sorafenib (0-10 µM) for 72 h. In all six DT-derived cell lines, we found that sorafenib significantly decreased proliferation in a dose-dependent manner relative to HDF controls ( Figure 1A and B). Maximum effect was observed at 10 µM concentration of sorafenib with DTFAP4 demonstrating ~90% decrease in proliferation. We next investigated drug effects on invasion by treating DT-derived cell lines with 5 µM of sorafenib for 24 h. Patientderived DTs showed high levels of invasion in the Matrigel assay while HDF controls showed minimal levels of invasion. Sorafenib strongly inhibited DT invasiveness. Representative imaging is shown in Figure 2A . Following sorafenib treatment, relative decrease in invasion was ~85% in both DTFAP4 and DTS8 cells (P < 0.0001), with DTS8 approaching 90% decrease ( Figure 2B ).
Sorafenib targets the Ras/MEK/ERK and PI3K/Akt/ mTOR pathways
To investigate potential mechanisms of sorafenib activity in DTs, we performed receptor tyrosine kinase signaling arrays using DT-derived cell lines obtained from both FAP (DTFAP4) and sporadic (DTS8) tumors. Following incubation with 5 µM sorafenib for 0-2 h time, we identified two dominant signaling pathways that were affected by sorafenib treatment including the Ras/MEK/ERK and PI3K/Akt/mTOR pathways ( Supplementary  Figures 1 and 2 , available at Carcinogenesis Online). Sorafenib was effective in altering signaling patterns in DT cell lines derived from both FAP and sporadic tumors. We next performed western blot to validate the pathways identified in the signaling arrays. DTS6 cells derived from a sporadic mesenteric tumor were treated with 5 µM sorafenib for 0, 24, 48 and 72 h time intervals. Consistent with the signaling arrays, immunoblot analysis revealed that sorafenib inhibited phospho-and total MEK levels in a time-dependent manner ( Figure 3A ). This effect also correlated with inhibition of phospho-ERK, most notably after 72 h, although total ERK levels remained unchanged ( Figure 3A) . In contrast, sorafenib treatment had no effect on phospho-or total MEK and ERK protein levels in HDF controls, suggesting that tumor cells demonstrate a more sensitive and sustainable response to sorafenib than fibroblast controls ( Figure 3A) .
Inhibitors of mammalian target of rapamycin (mTOR) are currently under investigation for treatment of DTs. To determine sorafenib effects on PI3K/Akt/mTOR signaling, we performed western blot on Akt and found inhibition of both phospho-and total Akt levels in a time-dependent manner ( Figure 3B ). We also examined expression of downstream effectors including 4E-BP1 and eIF4E following 0-72 h of sorafenib treatment. We found that sorafenib decreased phospho-4E-BP1 at all three treatment points; notably, sorafenib did not inhibit total 4E-BP1, a negative regulator of eIF4E, which in turn is a key mediator of translation initiation ( Figure 3B ). Subsequently, sorafenib demonstrated dramatic inhibition of phospho-and total eIF4E following treatment ( Figure 3B ). Of note, there was no synergistic or combinatorial effect of sorafenib and everolimus treatment on proliferation beyond sorafenib monotherapy in DT-derived cells (data not shown).
Everolimus inhibits mTOR signaling in desmoid-derived cells
Deregulated mTOR signaling contributes to a variety of cancer phenotypes via alterations in protein synthesis and cell proliferation. Given our findings demonstrating sorafenib inhibition of mTOR signaling, we sought to determine the synergistic effects of sorafenib with everolimus, an mTOR inhibitor currently in clinical use as an immunosuppressant as well as anticancer agent. Initially, DT-derived cells were incubated with 0.1-100 nM everolimus for 24 h. Phospho-and total eIF4E levels were minimally affected or even slightly increased when DTs were exposed to everolimus monotherapy (Figure 4) . Everolimus decreased phospho-S6K levels at 10 and 100 nM concentrations, whereas total S6K levels were not significantly altered. In contrast, the combination of sorafenib and everolimus effectively decreased phospho-S6K levels, especially at higher everolimus concentrations (Figure 4) . DT cells treated with everolimus and 5 µM sorafenib for 24 h had significant decrease in phosphoeIF4E levels, consistent with effects seen with sorafenib monotherapy ( Figure 3B ).
Discussion
Effective and durable treatments for DTs have been elusive due to the heterogeneous nature of the disease. Recently, the multikinase inhibitor sorafenib has emerged as a promising treatment option for DT patients (16) . While these initial findings have generated cautious optimism, the therapeutic mechanism underlying sorafenib effects in DTs has not yet been elucidated. Here, we sought to explore the molecular mechanism of sorafenib action in DT-derived cell lines from both familial and sporadic tumors. We showed that sorafenib significantly decreased both proliferation and invasion in multiple DT cell lines. Furthermore, this effect appeared to be mediated via both the Ras/MEK/ERK and PI3K/Akt/mTOR pathways by signaling array and western blot analysis.
Although surgical resection and/or radiotherapy remain the standard treatment for DTs, there has been growing interest in the role of systemic therapies over the last decade (17) . In the published 10-year experience (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) ) from one of the largest DT centers in the USA, systemic therapy was used in 28% of patients-either as an adjunct to surgery and/or radiotherapy, or as stand-alone therapy where these more conventional modalities were contraindicated-compared with only 6% in the historic cohort spanning 1965-94 (18) . Systemic agents including selective estrogen receptor modulators, non-steroidal anti-inflammatory drugs, cytotoxic agents and tyrosine kinase inhibitors have met with mixed response (4) (5) (6) (7) (8) (9) (10) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Whereas the RECIST (response evaluation criteria in solid tumors) 1.1 rate for imatinib has been <10% (28) , retrospective review of a small sample of patients with unresectable disease revealed that sorafenib treatment resulted in partial response or stable disease in 96% of patients at a median of 6 months of treatment (16) . As a result of these findings, sorafenib was added as an option for systemic therapy for DTs to the 2012 National Comprehensive Cancer Center (NCCN) Guidelines for soft tissue sarcoma (29) . In our study, we found that sorafenib significantly decreased proliferation and invasion in DT-derived cell lines, with maximum reduction in proliferation and invasion approaching 90% following treatment (Figures 1 and 2 ). This observation was seen in multiple cell lines obtained from patients with both sporadic and familial forms of the disease. Sorafenib had little effect on proliferation in HDF controls, demonstrating that DT tumor cells are particularly sensitive to the drug in a dose-dependent manner. Sorafenib is known to inhibit Raf serine/threonine kinase isoforms in vitro (30, 31) . Downstream, sorafenib has also been shown to inhibit ERK signaling by decreasing ERK phosphorylation, resulting in decreased proliferation, invasion and tumor growth. Consistent with this, we show that sorafenib decreased phospho-and total MEK as well as phospho-ERK levels in DT cells ( Figure 3A) . Our data provide a compelling mechanism for the clinical observations made by Gounder et al. (16) in which ~70% of patients reported improvement in DT symptoms following treatment with sorafenib, potentially through inhibition of the Ras/MEK/ERK signaling pathway. Interestingly, symptomatic relief was reported to be rapid and striking in several patients following sorafenib therapy, even in cases where tumor size was not significantly affected, suggesting a potential therapeutic benefit from decreased invasion/infiltration on surrounding structures.
Sorafenib Decreases Proliferation in Sporadic DT-derived Cells
As a multikinase inhibitor, sorafenib has also demonstrated anticancer effects through decreased PDGFRβ activity and Akt phosphorylation in multiple tumor cell lines (31) (32) (33) . Oncogenic activation of the PI3K/Akt/mTOR pathway leads to deregulated cell metabolism, survival, proliferation and growth. Downstream of PI3K/Akt signaling, mTOR regulates protein synthesis by forming distinct complexes that phosphorylate the eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase (S6K). These factors play a key role in translation initiation in which the ribosome is recruited to the mRNA. 4E-BP1 is a negative repressor of eIF4E; 4E-BP1 phosphorylation and subsequent dissociation from eIF4E relieve translational suppression. Interaction between 4E-BP1 and eIF4E is frequently dysregulated in cancer, leading to increased eIF4E activity and subsequent tumor proliferation and growth. As such, targeting eIF4E activation and phosphorylation through inhibition of the PI3K/Akt/mTOR pathway may be effective as an anticancer strategy (34, 35) . In DT cells, we found that sorafenib decreased phospho-and total Akt levels in a time-dependent manner ( Figure 3A) . Downstream, this resulted in decreased phospho-4E-BP1, while total 4E-BP1 levels remained unchanged ( Figure 3B ). Since 4E-BP1 represses eIF4E activity, we also showed that phospho-and total eIF4E levels decreased after sorafenib treatment. Taken together, our findings suggest that sorafenib may have antitumorigenic effects on DTs through inhibition of PI3K/Akt/mTOR signaling and inactivation of eIF4E-mediated translation. Interestingly, Rahmani et al. (36) showed that sorafenib induced apoptosis in human leukemia cells through dephosphorylation of eIF4E and subsequent downregulation of the antiapoptotic protein Mcl-1. While our study did not specifically address apoptosis, sorafenib effects on translation are clearly multifactorial and warrant further study in DTs and other solid tumors.
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β-Actin p-eIF4E eIF4E Figure 4 . Combination sorafenib and everolimus effects in DT-derived cells. DT-derived cells were incubated with 0.1-100 nM everolimus for 24 h. Everolimus decreased phospho-S6K levels in a dose-dependent manner, whereas total levels were largely unchanged. Everolimus, in combination with 5 µM sorafenib, strongly decreased phospho-S6K levels in a dose-dependent manner. In contrast, everolimus effects on eIF4E were minimal. Sorafenib also decreased phospho-and total Akt levels, most significantly after 72 h of treatment (B). Downstream, phospho-4E-BP1 levels decreased after sorafenib treatment; notably, sorafenib did not inhibit total 4E-BP1, a negative regulator of eIF4E. Subsequently, sorafenib demonstrated dramatic inhibition of phospho-and total eIF4E following long-term treatment (B).
Many human malignancies have dysregulated Ras/MEK/ERK and PI3K/Akt/mTOR signaling pathways, leading to aberrant proliferation and invasion. The two pathways appear to interact at multiple points with feedback loops creating compensatory signaling when one path is inhibited (37). Li et al. (33) showed that hepatocellular carcinoma cells developed resistance to the mTOR inhibitor rapamycin via PDGFRβ-dependent activation of the PI3K/Akt and MAPK pathways. This resistance was overcome when hepatocellular carcinoma cells were subsequently treated with sorafenib, thereby blocking PDGFRβ activation and restoring antitumor sensitivity to rapamycin. In a related study, Gedaly et al. (38) demonstrated that combination treatment using PI-103, a small molecule inhibitor of PI3K and mTOR, with sorafenib was more effective than monotherapy in decreasing hepatocellular carcinoma proliferation and tumorigenesis through synergistic inhibition of both PI3K/Akt/mTOR and Ras/RAF/MAPK pathways. These studies suggest that dual targeting of overlapping pathways may overcome resistance or 'escape' mechanisms, leading to enhanced tumor response and more durable treatment outcomes for patients. Consistent with this hypothesis, we found that everolimus alone did not reduce phospho-or total eIF4E levels; in fact, phospho-eIF4E levels appeared to increase slightly with treatment, consistent with potential resistance effects ( Figure 4) . Addition of sorafenib to everolimus, however, overcame monotherapy resistance and demonstrated a dramatic decrease in phospho-eIF4E levels. Furthermore, sorafenib plus everolimus appeared to decrease phosphorylation of the ribosomal protein and mTOR effector S6K in an additive manner. In agreement with our data, Choo et al. (39) found that rapamycin differentially inhibited S6K and 4E-BP1 in acute versus long-term treatments, whereas S6K inhibition was maintained after 24-48 h of treatment, 4E-BP1 recovered phosphorylation and disassociated from eIF4E after 24 h of treatment, indicative of rapamycin resistance. Of note, we found no synergistic or combinatorial effect of sorafenib and everolimus treatment on proliferation beyond sorafenib monotherapy, suggesting that everolimus effects on proliferation may be minimal in DTs or, at least, in the patient-derived cell lines tested.
In conclusion, we have shown that sorafenib decreases proliferation and invasion in DT-derived samples, potentially through inhibition of the Ras/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Additional sorafenib effects on eIF4E and S6K regulation suggest that sorafenib may be a therapeutic option in the treatment of DTs through inhibition of translation initiation. While prior studies have shown that select subtypes of soft tissue sarcomas have been successfully targeted with mTOR inhibitors, dual/multiple pathway inhibition with combination treatment may be a more optimal approach for therapy in DTs.
